Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

AcelRx Pharmaceuticals Q3 2023 Gaap EPS $(0.08) Beats $(0.28) Estimate, Sales $117.00K Miss $130.00K Estimate

Author: Benzinga Newsdesk | November 08, 2023 06:16pm
AcelRx Pharmaceuticals (NASDAQ:ACRX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.28) by 71.43 percent. This is a 91.49 percent increase over losses of $(0.94) per share from the same period last year. The company reported quarterly sales of $117.00 thousand which missed the analyst consensus estimate of $130.00 thousand by 10.00 percent. This is a 76.92 percent decrease over sales of $507.00 thousand the same period last year.

Posted In: ACRX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist